Citations

Showing 10 of 108104 citations.

Integrating the experience: Principles for digital transformation across the patient journey
Mooij, Marnie de , Foss, Olivia, de Mooij, Marnie , Foss, Olivia R., Brost, Brian

Mayo Clinic

DIGITAL HEALTH | March 31, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762210891

10.1177/20552076221089100 | PMID 35392253 Get It

As medical science advances and the population ages, the prevalence of chronic conditions has also grown. The traditional model of care, with its focus on acute and episodic issues within the office visit, is not designed to meaningfully address long-term patient needs. With COVID-19 has come unprecedented digital adoption, bringing health care delivery to a critical juncture. While digital tools and technologies present vast opportunities for democratizing and decentralizing care experiences, their piecemeal application to the existing “sick care” model and its information technology infrastructure will not only limit their value, but will inevitably add cost, inefficiency, and burden to care teams. In order to build upon this momentum and reap the full benefits of practice digitization, care model transformation must occur. This entails holistically reexamining how every component of the health care experience, from the digital tools to visit interactions, synchronizes to address the full continuum of patient needs throughout the journey. By doing this, care shifts away from one-size-fits-all, fragmented strings of visits, toward seamless experiences that adapt to patients’ needs in real-time while integrating within their daily lives. Rather than acting as a substitute for care, technology instead is vital to promoting and amplifying the impact of all those involved. To achieve this, this paper outlines 10 principles for restructuring care to incorporate digital health capabilities. Each describes how all care model components work as a system that aligns with patient needs. By doing this, technology is now an integral in supporting relationships across the full continuum of care.
Assessing Nordihydroguaiaretic Acid Therapeutic Effect for Glioblastoma Multiforme
Manciu, Felicia , Guerrero, Jose, Bennet, Kevin E. , Chang, Su-Youne , Rahman, Masum , Lopez, Lizbeth V. Martinez, Chantigian, Siobhan, Castellanos, Mariana, Manciu, Marian , Manciu, Felicia S , Chang, Su-Youne

Mayo Clinic

Sensors | March 30, 2022 | Volume: 22 | Issue: 7 | Pages: 2643

10.3390/s22072643 | PMID 35408257 Get It

In this study, we demonstrate that Raman microscopy combined with computational analysis is a useful approach to discriminating accurately between brain tumor bio-specimens and to identifying structural changes in glioblastoma (GBM) bio-signatures after nordihydroguaiaretic acid (NDGA) administration. NDGA phenolic lignan was selected as a potential therapeutic agent because of its reported beneficial effects in alleviating and inhibiting the formation of multi-organ malignant tumors. The current analysis of NDGA’s impact on GBM human cells demonstrates a reduction in the quantity of altered protein content and of reactive oxygen species (ROS)-damaged phenylalanine; results that correlate with the ROS scavenger and anti-oxidant properties of NDGA. A novel outcome presented here is the use of phenylalanine as a biomarker for differentiating between samples and assessing drug efficacy. Treatment with a low NDGA dose shows a decline in abnormal lipid-protein metabolism, which is inferred by the formation of lipid droplets and a decrease in altered protein content. A very high dose results in cell structural and membrane damage that favors transformed protein overexpression. The information gained through this work is of substantial value for understanding NDGA’s beneficial as well as detrimental bio-effects as a potential therapeutic drug for brain cancer.
AI-Enabled Advanced Development for Assessing Low Circulating Blood Volume for Emergency Medical Care: Comparison of Compensatory Reserve Machine-Learning Algorithms
Techentin, Robert W., Poole, Ruth J., Dacy, Ashley C., Carlson, Ashli N., Cardin, Sylvain , Haider, Clifton R. , Holmes, David R. , Wiggins, Chad C. , Joyner, Michael J. , Inan, Omer T. , Holmes Iii, David R, Wiggins, Chad C , Curry, Timothy B. , Inan, Omer T , Joyner, Michael J , Convertino, Víctor A. , III, David R. Holmes

Mayo Clinic

Sensors | March 30, 2022 | Volume: 22 | Issue: 7 | Pages: 2642

10.3390/s22072642 | PMID 35408255 Get It

The application of artificial intelligence (AI) has provided new capabilities to develop advanced medical monitoring sensors for detection of clinical conditions of low circulating blood volume such as hemorrhage. The purpose of this study was to compare for the first time the discriminative ability of two machine learning (ML) algorithms based on real-time feature analysis of arterial waveforms obtained from a non-invasive continuous blood pressure system (Finometer®) signal to predict the onset of decompensated shock: the compensatory reserve index (CRI) and the compensatory reserve metric (CRM). One hundred ninety-one healthy volunteers underwent progressive simulated hemorrhage using lower body negative pressure (LBNP). The least squares means and standard deviations for each measure were assessed by LBNP level and stratified by tolerance status (high vs. low tolerance to central hypovolemia). Generalized Linear Mixed Models were used to perform repeated measures logistic regression analysis by regressing the onset of decompensated shock on CRI and CRM. Sensitivity and specificity were assessed by calculation of receiver-operating characteristic (ROC) area under the curve (AUC) for CRI and CRM. Values for CRI and CRM were not distinguishable across levels of LBNP independent of LBNP tolerance classification, with CRM ROC AUC (0.9268) being statistically similar (p = 0.134) to CRI ROC AUC (0.9164). Both CRI and CRM ML algorithms displayed discriminative ability to predict decompensated shock to include individual subjects with varying levels of tolerance to central hypovolemia. Arterial waveform feature analysis provides a highly sensitive and specific monitoring approach for the detection of ongoing hemorrhage, particularly for those patients at greatest risk for early onset of decompensated shock and requirement for implementation of life-saving interventions.
Clinical Presentation and Management of Methicillin-Resistant Staphylococcus aureus Pericarditis—Systematic Review
Radovanovic, Milan , Petrović, Marija , Hanna, Richard D. , Nordstrom, Charles W. , Calvin, Andrew D. , Barsoum, Michel K., Milosavljevic, Natasa, Jevtic, Dorde , Sokanovic, Mladen, Dumic, Igor , Jevtic, Djordje , Dumic, Igor , Calvin, Andrew D , Sokanovic, Mladen

Mayo Clinic

Journal of Cardiovascular Development and Disease | March 30, 2022 | Volume: 9 | Issue: 4 | Pages: 103

10.3390/jcdd9040103 | PMID 35448079 Get It

In the expanding era of antibiotic resistance, new strains of Staphylococcus aureus have emerged which possess resistance to traditionally used antibiotics (MRSA). Our review aimed to systematically synthesize information on previously described MRSA pericarditis cases. The only criterion for inclusion was the isolation of MRSA from the pericardial space. Our review included 30 adult and 9 pediatric patients (aged: 7 months to 78 years). Comorbid conditions were seen in most adult patients, whereas no comorbidities were noted amongst the pediatric patients. Pericardial effusion was found in 94.9% of cases, with evidence of tamponade in 83.8%. All cases isolated MRSA from pericardial fluid and 25 cases (64.1%) had positive blood cultures for MRSA. Pericardiocentesis and antibiotics were used in all patients. The mortality rate amongst adults was 20.5%, with a mean survival of 21.8 days, and attributed to multi-organ failure associated with septic shock. No mortality was observed in the pediatric population. In adult patients, there was no statistical difference in symptom duration, antibiotic duration, presence of tamponade, age, and sex in relation to survival. Conclusion: MRSA pericarditis often presents with sepsis and is associated with significant mortality. As such, a high clinical suspicion is needed to proceed with proper tests such as echocardiography and pericardiocentesis. In more than one third of the cases, MRSA pericarditis occurs even in the absence of documented bacteremia.
Case 10-2022: A 78-Year-Old Man with Marked Ventricular Wall Thickening
Lubitz, Steven A. , Tsang, Teresa S.M. , Tower‐Rader, Albree, Karaa, Amel , Dudzinski, David M. , Lubitz, Steven A , Tower-Rader, Albree, Karaa, Amel , Pellikka, Patricia A.

Mayo Clinic

New England Journal of Medicine | March 30, 2022 | Volume: 386 | Issue: 13 | Pages: 1266-1276

10.1056/nejmcpc2201230 | PMID 35353965 Get It

Cold whole blood transfusion in civilian trauma patients requiring emergent resuscitation: a retrospective cohort study
Fischmann, Marianna Martini , Bryant, Sandra C. , Zielinski, Martin D. , Stubbs, James R.

Mayo Clinic

No container title available | March 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1413454/v1 Get It

Abstract Background: The use of cold whole blood (WB) is rapidly resurging as one of the treatment modalities of choice for the initial resuscitation of civilian trauma patients across the United States. The purpose of our study was to evaluate the effectiveness and safety of cold whole blood (WB) as compared to blood component therapy (BCT) in resuscitation of civilian trauma patients. Methods: This was a retrospective cohort study of trauma patients who received at least one unit of WB transfusion during emergent resuscitation between November 2015 and October 2019 at a level I trauma center. Primary outcome was mortality up to 30 days after trauma. Secondary outcomes included overall blood product utilization and incidence of transfusion reactions. Outcomes were compared between patients who received WB and a cohort receiving BCT who did not receive WB matched for age, sex, mechanism of injury, heart rate, systolic blood pressure, Glasgow Coma Scale, injury severity score, and FAST results. Results: We included 78 patients who received WB transfusion and 78 matched controls. Within 30 days of injury, there were 19 deaths (24.4%) in the WB cohort and 28 (35.9%) deaths in controls (hazard ratio 0.62, 95% CI 0.33 to 1.15, p = 0.086). Patients in the WB cohort received as many units of blood products as controls (median number of units was 10 (IQR 6, 20) vs. 12 (IQR 6, 23), p = 0.43). The incidence of any transfusion reactions was similar between groups (7.7% in WB vs 9.0% in controls, p = 0.78). Life-threatening reactions did not occur in any of the groups. Conclusions: There was no mortality difference between patients receiving cold WB and BCT. Cold WB was safe in this cohort with no life-threatening transfusion reactions.
The Arched Rainbow Brow in Thyroid Eye Disease
Tran, Ann Q. , Yang, Cameron, Tooley, Andrea A. , Mahan, Marielle, Jamerson, Emery C., Kazim, Michael, Glass, Lora R. Dagi

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | March 30, 2022 | Volume: 38 | Issue: 5 | Pages: 469-474

10.1097/iop.0000000000002168 | PMID 35353778 Get It

Purpose: To morphologically describe and mathematically quantify a novel clinical feature of thyroid eye disease (TED). Methods: A retrospective study was conducted of TED patients and age-sex-matched normal controls. The arched Rainbow Brow appearance in TED patients was determined by unanimous agreement of 3 oculoplastic surgeons. Eyebrow curvature was assessed by plotting 15 points along the eyebrow in ImageJ. The fourth-degree polynomial (y = ax4 + bx3 + cx2 + dx + e) was fitted to each eyebrow. Results: Two hundred seventy-one eyes were analyzed (200 TED and 71 age-sex-matched normal controls). A Rainbow Brow was identified in 42% of TED patients. A unilateral Rainbow Brow was seen in 15% of patients. The fourth-degree polynomial coefficients yielded significant differences between Rainbow Brow patients and age-sex-matched normal controls for the coefficients a, b, c, and d. Similar analysis of TED patients with and without a Rainbow Brow showed differences in coefficients a and b. Age >50 years (p = 0.009) and the presence of brow fat expansion (p < 0.001) were associated with the presence of a Rainbow Brow. Proptosis >24 mm showed a trend toward association with the presence of a Rainbow Brow (p = 0.057). When considering the contribution of these features in a multivariable analysis, only brow fat expansion was a significant contributing factor (p = 0.009). Conclusions: The Rainbow Brow is a distinct entity in TED and is likely consequent to brow fat pad expansion. Patients with a Rainbow Brow have different eyebrow curvature as compared to both normal age-sex-matched controls and TED patients without a Rainbow Brow.
Gonioscopy-Assisted Transluminal Trabeculotomy for Glaucoma: 1-Year Outcomes and Success Predictors
Faria, Bruno M., Costa, Vital P., Melillo, Gustavo H.L., Daga, Fabio B., Scoralick, Ana L.B., Paranhos, Augusto, Kanadani, Fábio N., Prata, Tiago S., Faria, Bruno M., Costa, Vital P., Melillo, Gustavo H.L., Daga, Fabio B., Scoralick, Ana L.B., Paranhos, Augusto, Kanadani, Fábio N., Prata, Tiago S.

Mayo Clinic

Journal of Glaucoma | March 30, 2022 | Volume: 31 | Issue: 6 | Pages: 443-448

10.1097/ijg.0000000000002025 | PMID 35353767 Get It

Précis: Our results suggest gonioscopy-assisted transluminal trabeculotomy (GATT) as an effective and safe option for the surgical management of open-angle glaucoma (OAG). Older age was the only risk factor for failure in our analysis. Purpose: To report 12-month clinical outcomes, safety profile and success predictors of GATT in patients with OAG. Patients and Methods: A retrospective study of patients (18 y old and above) with medically uncontrolled OAG who underwent GATT as a solo procedure or combined with phacoemulsification (PHACO-GATT) between January 2018 and January 2020. Success at 12 months (primary outcome) was defined as intraocular pressure (IOP) <15 mm Hg, with an IOP reduction of at least 20%, OR a reduction of at least 2 glaucoma medications, compared with baseline. Secondary outcomes were success predictors and safety parameters. Results: A total of 73 eyes (GATT=38; PHACO-GATT=35) from 58 patients with a mean age of 54.8±11.6 years were included. Overall, after 12 months of follow-up, the mean IOP was reduced from 24.9±8.5 to 12.1±2.1 mm Hg (P<0.001). The mean number of glaucoma medications was reduced from 3.5±0.7 to 1.2±1.2 (P<0.001). The success rate was 87% at 12 months, with no significant differences between GATT (85%) and PHACO-GATT (91%) eyes (P=0.330). Age was the only factor significantly associated with surgical success (hazard ratio=1.35; P=0.012; after adjusting for preoperative IOP and number of glaucoma medications). Patients older than 60 years had a significant greater chance of failure (hazard ratio=10.96; P=0.026) compared with those younger than 60 years. The most common postoperative complication was transient hyphema (39%; median duration, 5 d). No sight-threatening adverse event was documented. Conclusions: GATT was effective and safe at lowering IOP with or without cataract extraction in OAG. Patients 60 years or older had a higher risk of failure compared with those younger in age.
The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease
Patil, Seema , Bhat, Shubha , Limdi, Jimmy K. , Cross, Raymond K. , Cross, Raymond , Farraye, Francis A.

Mayo Clinic

Inflammatory Bowel Diseases | March 30, 2022 | Volume: 28 | Issue: 12 | Pages: 1915-1923

10.1093/ibd/izac048 | PMID 35353189 Get It

Lay Summary Biosimilar medications have the potential to significantly reduce the cost of treatment in patients with inflammatory bowel disease. Observational studies have shown similar efficacy and safety of biosimilars to biologic reference products. Shared decision-making is crucial to the successful implementation of these agents.
Experiences of Gender Inequity Among Women Physicians Across Career Stages: Findings from Participant Focus Groups
Salinas, Manisha , Abraham, Helayna , Harris, Courtney E. , Carey, Elise C. , Khalsa, Tejinder, Mauck, Karen F. , Feely, Molly A., Licatino, Lauren K. , Moeschler, Susan M. , Bhagra, Anjali , Chesak, Sherry S. , Feely, Molly, Licatino, Lauren, Moeschler, Susan, Harris, Courtney E

Mayo Clinic

Women's Health Reports | March 30, 2022 | Volume: 3 | Issue: 1 | Pages: 359-368

10.1089/whr.2021.0051 | PMID 35415713 Get It